US PharmacistSpotlight on Multiple Myeloma Treatment and Pharmacist Support

This comprehensive review provides evidence-based guidance on multiple myeloma pharmacotherapy, covering frontline combination regimens and relapsed/refractory treatments across multiple drug classes. The material emphasizes practical considerations for medication management, adverse effect monitoring, and patient counseling essential for optimal pharmaceutical care delivery.

⚕️ Key Clinical Considerations ⚕️

• Drug Class Integration: Frontline regimens typically combine CD38-directed monoclonal antibodies, proteasome inhibitors, immunomodulatory drugs, and steroids with specific dosing protocols and administration routes requiring careful verification and patient education.
• Route Optimization: Subcutaneous daratumumab and weekly bortezomib administration reduce infusion time and neuropathy risk respectively, while IV-to-PO steroid conversions can minimize parenteral drug use in appropriate clinical settings.
• REMS Program Compliance: IMIDs, bispecific antibodies, and CAR-T therapies require mandatory Risk Evaluation and Mitigation Strategy enrollment with pharmacist involvement in patient education and safety monitoring protocols.
• Adverse Effect Recognition: Peripheral neuropathy from proteasome inhibitors, venous thromboembolism risk with IMIDs plus steroids, and oral toxicities from bispecific antibodies require proactive monitoring and symptom-directed supportive care interventions.
• Drug Interaction Management: Strong CYP3A4 inhibitors and inducers significantly affect bortezomib and ixazomib concentrations, while viral prophylaxis is mandatory with proteasome inhibitor therapy due to reactivation risks.

🎯 Clinical Practice Impact 🎯

• Patient Communication: Pharmacists should counsel patients on expected adverse effects, particularly peripheral neuropathy symptoms that may be mistakenly attributed to comorbid conditions like diabetes, and provide clear instructions for symptom reporting to oncology teams.
• Practice Integration: Verification protocols must include confirmation of appropriate drug combinations, dosing based on patient-specific factors including BSA limitations for carfilzomib, and validation of premedication orders for infusion reaction prevention with monoclonal antibodies.
• Risk Management: Implementation of VTE prophylaxis screening tools (IMPEDE/SAVED scores) for IMID combinations, viral prophylaxis protocols for proteasome inhibitors, and specialized supportive care measures for oral toxicities associated with newer bispecific antibody therapies.
• Specialized Care Coordination: Pharmacists can serve as authorized representatives for REMS programs, facilitate outpatient administration models for bispecific antibodies and CAR-T monitoring, and optimize infusion protocols to reduce chair time and improve patient experience.

More in Multiple Myeloma